RxDoctor Payments Data

Jessica Deleo, APRN

Adult Health · Rockledge, FLNPI 1285239764

Payments from drug & device makers

$10,120in general payments, 2019–2025

Across 216 payments — averaging $46.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Johnson & Johnson$862
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$709
  • Sanofi-aventis U.S. LLC$417
  • Boehringer Ingelheim$325
  • E.r. Squibb & Sons, L.L.C.$324
  • plus $781 from 12 others

What the payments were for

  • Travel & lodging$3,64936%
  • Food & beverage$6,42563%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,120 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$139,420
Medicare patients
535
Services billed
2,365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban295$341,378
XareltoRivaroxaban195$223,237
EntrestoSacubitril/Valsartan68$91,383
JardianceEmpagliflozin33$58,274
Metoprolol Succinate327$4,822
Dabigatran EtexilateDabigatran Etexilate Mesylate14$3,444
Diltiazem 24hr Er (Cd)Diltiazem Hcl69$2,059
Amiodarone Hcl148$1,999
Flecainide Acetate45$1,429
Propafenone Hcl11$1,033
Carvedilol102$1,031
Losartan Potassium77$770
Hydralazine Hcl19$629
Diltiazem Hcl16$549
SotalolSotalol Hcl31$520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$77$341,378295 claims
Johnson & JohnsonXarelto$862$223,237195 claims
NovartisEntresto$26$91,38368 claims
Boehringer IngelheimJardiance$325$58,27433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.

Other adult health in Rockledge

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →